(Q37396438)

20 August 2017

1 reference

title

Antiangiogenic therapy for metastatic breast cancer: current status and future directions (English)

1 reference

20 August 2017

angiogenesis inhibitor

1 reference

inferred from title

metastatic breast cancer

1 reference

Arlene Chan

1

1 reference

20 August 2017

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

69

1 reference

20 August 2017

2

1 reference

20 August 2017

167-181

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200969020-00003

20 August 2017

0 references

cites work

Vasculogenic mimicry and tumor angiogenesis

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200969020-00003

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 January 2018

1 reference

12 December 2020

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

12 December 2020

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

1 reference

12 December 2020

Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy

1 reference

12 December 2020

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

1 reference

12 December 2020

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

12 December 2020

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

1 reference

12 December 2020

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.

1 reference

12 December 2020

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

12 December 2020

Antiangiogenic chemotherapeutic agents

1 reference

12 December 2020

ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Vascular endothelial growth factor: basic science and clinical progress

1 reference

12 December 2020

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

1 reference

12 December 2020

Imaging angiogenesis: applications and potential for drug development

1 reference

12 December 2020

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

1 reference

12 December 2020

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

12 December 2020

Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models.

1 reference

12 December 2020

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

12 December 2020

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

1 reference

12 December 2020

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

12 December 2020

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

1 reference

12 December 2020

Raf: a strategic target for therapeutic development against cancer

1 reference

12 December 2020

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

12 December 2020

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

1 reference

12 December 2020

A physiologic imaging pilot study of breast cancer treated with AZD2171.

1 reference

12 December 2020

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

12 December 2020

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer

1 reference

12 December 2020

Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells

1 reference

12 December 2020

Sunitinib: from rational design to clinical efficacy

1 reference

12 December 2020

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

1 reference

12 December 2020

Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors

1 reference

12 December 2020

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

1 reference

12 December 2020

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

1 reference

12 December 2020

Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer

1 reference

12 December 2020

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

12 December 2020

Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin

1 reference

12 December 2020

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

1 reference

12 December 2020

The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era.

1 reference

12 December 2020

Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies

1 reference

12 December 2020

Pazopanib: a novel multitargeted tyrosine kinase inhibitor

1 reference

12 December 2020

Building a better Trap

1 reference

12 December 2020

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

1 reference

12 December 2020

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

12 December 2020

Regression of established tumors and metastases by potent vascular endothelial growth factor blockade

1 reference

12 December 2020

Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway

1 reference

12 December 2020

Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool

1 reference

12 December 2020

Vascular Endothelial Growth Factor (VEGF) Expression in Human Pituitary Adenomas and Carcinomas

1 reference

12 December 2020

10.2165/00003495-200969020-00003

Identifiers

DOI

1 reference

PubMed ID

19228074

Dimensions Publication ID

20 August 2017

0 references

1 reference

PubMed ID

19228074